Combining zedoresertib with lunresertib yielded activity in patients with CCNE1-altered platinum-resistant ovarian cancer in the phase 1 MYTHIC trial.
Timothy A. Yap, MBBS, PhD, FRCP
Advertisement
Articles by Timothy A. Yap, MBBS, PhD, FRCP
According to Timothy A. Yap, MBBS, PhD, FRCP, there is an unmet need in oncology for treating patients with CCNE1, FBXW7, and PPP2R1A genomic alterations.
Timothy A. Yap, MBBS, PhD, FRCP, presented data from the MYTHIC trial, demonstrating a 60% ORR at the RP2D in patients with CCNE1-amplified PROC.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
VT-EBV-N Yields Durable Disease-Free Survival in Pretreated ENKTL
2
Tisa-Cel Yields Enduring Remissions in Younger High-Risk B-ALL Population
3
Anbenitamab Regimen Meets Phase 3 End Points in HER2+ Breast Cancer
4
Investigators Halt Phase 3 Trial of Sacituzumab Govitecan Combo in NSCLC
5